Hormone Tx for Prostate CA No Better Long Term

Share this content:
ASTRO: Long-Term Hormonal Tx No Better for Certain Prostate CA
ASTRO: Long-Term Hormonal Tx No Better for Certain Prostate CA

HealthDay News -- For men with intermediate-risk prostate cancer, long-term hormonal therapy offers no benefit over short-term hormonal therapy, according to a study presented at the annual meeting of the American Society for Therapeutic Radiation Oncology, held from Sept. 22 to 25 in Atlanta.

Amin Mirhadi, M.D., from the Cedars Sinai Medical Center in Los Angeles, and colleagues compared the effect of long-term versus short-term hormonal therapy using data from 133 patients with intermediate-risk prostate cancer enrolled in the RTOG 9202 trial. Seventy-four patients were treated with initial androgen deprivation only (STAD) and 59 received long-term adjuvant androgen deprivation (LTAD).

The researchers found that with a median follow-up of more than 11 years, 39 patients in the STAD group and 33 in the LTAD group were alive. Overall survival (OS) was not significantly different between the groups (10-year estimates, 61 percent in STAD versus 65 percent in LTAD; P = 0.53). Ten-year disease-specific survival (DSS) was not significantly different between the groups (96 percent in each group; P = 0.72), nor were prostate specific antigen failure rates (53 and 55 percent, respectively; P = 0.99).

"Most clinicians have felt that 'more was better' when it came to blocking testosterone in prostate cancer patients; however, results for the specific end points we focused on, OS and DSS, indicate that this was clearly not the case," Mirhadi said in a statement.

One author disclosed a financial relationship with Astellas.

Press Release
More Information

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs